Compare Incyte Corporation (INCY) vs Reddit Inc (RDDT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Reddit Inc — how do they compare? Incyte Corporation trades at $115.71 (market cap $23.11B), while Reddit Inc trades at $182.46 (market cap $34.97B). The key difference: Reddit Inc is the larger of the two by market cap, and Incyte Corporation is trading nearer its 52-week high, Reddit Inc nearer its low. Which is the better fit depends on your goals.
| INCY | RDDT | |
|---|---|---|
Market Cap | $23.11B | $34.97B |
Sector | Health | Media |
52-Week High | $118.52 | $270.71 |
52-Week Low | $67.38 | $121.84 |
Enterprise Value | $19.13B | $32.22B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
Reddit (RDDT) trades at $181.67, showing modest daily gains of 0.21%. The stock faces bearish technical signals with key support at $178 and resistance at $184. Fundamentally, the company demonstrates strong profitability with 91.37% gross margins and 28.6% net income margin, though valuation ratios remain elevated with a P/E of 51.77. Recent earnings show mixed results with a Q3 2025 miss but subsequent beats, while Q2 2026 results are pending.
The investment outlook balances strong fundamental growth against high valuation and technical headwinds. Analyst consensus remains bullish with a $236.89 price target (62.96% buy ratings), but risks include competitive pressures in digital advertising and execution challenges in AI initiatives. The stock offers growth potential but requires careful monitoring of upcoming earnings and market sentiment shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Reddit Inc
Reddit Inc. operates a vast network of online communities organized around various interests, known as 'subreddits'. Functioning as a hybrid of a social media platform and a discussion forum, the company generates revenue primarily through advertising and premium subscriptions. Reddit is a major hub for user-generated content, trending news, and viral discussions, and it is a key player in the digital advertising and social media landscape.
Read more on RDDT →
